Women who inherit a defective BRCA1 or BRCA2 gene have risks for breast/ovarian cancer that are so high and apparently so selective that many mutation carriers choose to have the most likely targets for cancer surgically removed. Recent research has focused on better methods of treating such seemingly unavoidable hereditary cancers. Prevention has received much less attention so a positive test result for a cancer gene leaves carriers with very limited options.
Introduction
Women who inherit a defective BRCA1 or BRCA2 gene have risks for breast/ovarian cancer that are so high and apparently so selective that many mutation carriers choose to have the most likely targets for cancer surgically removed [1] [2] [3] [4] [5] [6] [7] . Recent research has focused on better methods of treating the cancers that seem unavoidable. Prevention has received much less attention so a positive test result for a cancer related mutation leaves carriers with very limited options.
In order to prevent BRCA1/2 related cancers, it may be important to understand why they seem to occur only in certain characteristic organs. Why would cancer just attack breasts and ovaries when every cell with a nucleus contains the same mutation? Functionally, both BRCA genes are general cell requirements because they encode products essential for checkpoint controls and for DNA repairs. How does inheritance of a defect in general cell requirements lead to cancers in specific target organs?
Here the possibility is tested that infection and chronic inflammation direct inherited cancers to specific organ targets. Evidence is overwhelming that chronic inflammation underlies many cancers and that some chronic infections can direct cancer to a specific organ. For example, hepatitis viruses target the liver for cancer because the liver has receptors for hepatitis viruses. Hepatitis B and C viruses do not cause cancer unless chronic inflammation follows infection, leading to DNA breaks [8, 9] . Many normal individuals recover and never develop liver cancer.
Inherited cancer related mutations are rare, making risks from chronic inflammatory conditions difficult to study. Results from epidemiology were used to approach this problem. Risks for cancers associated with inflammation in a specific organ were statistically combined from eleven published studies of known or likely mutation carriers. The resulting statistical summaries of cancer relative risks included over 25,000 carriers of any testable mutation in DNA damage responses depending on BRCA1 and BRCA2 gene products.
The rarity of BRCA1/2 mutations made it necessary to include all testable components in the subroutine that depends on functional BRCA1 and BRCA2 proteins. Figure 1 shows an approximate arrangement of the testable components in a model subroutine within the DNA damage response [10, 11] Strong evidence supports the idea that inactivating a gene encoding any of these components causes genomic instability and increases cancer risks. All the components in the model participate in DNA damage responses that can be induced by reactive oxygen products from inflammatory processes. These responses are double strand break repair by homologous recombination, repair of collapsed or stalled DNA replication forks, and prevention of hypersensitivity to DNA cross-linking agents. Cancer genome sequences rarely inactivate more than one gene in the same sub-routine.
Fanconi anemia (FA), ataxia-telangiectasia (A-T) and BRCA deficiency are hereditary cancer prone diseases caused by inactivation of one gene in the pathway containing BRCA1/2. In each condition there are increased numbers of chromosome breaks, large rearrangements, and/or regional gains and losses in chromosomes [Fig. 1, 12, 13] . Multiple steps in the repair of interstrand cross-links can fail when the FA pathway is compromised. A-T patients have elevated risks for DNA damage in tissues undergoing inflammation [14] and FA patients over-express inflammatory genes and proteins [15] . Cells that are deficient in any one of eight FA core complex proteins are defective in monoubiquitylation of FANCD2 and FANCI. This defect causes chromosome breakages and FA hypersensitivity to DNA cross-linking agents. (See footnote to Fig 1) .
Here, mutation carriers were found to have strikingly increased risks for cancers connected to known chronic inflammatory infections such as liver cancer, cervical cancer and stomach cancer. Risks increase hundreds of times in homozygotes and up to several-fold in heterozygotes. For BRCA1/2 related breast and ovarian cancers, cancer prevention data and evidence of immune responses suggest that chronic inflammation helps target these organs. Inflammation also disrupts normal cellular organization and architecture, further favoring cancer. Identifying and controlling chronic infections and inflammation may delay or prevent some hereditary cancers in mutation carriers.
Materials and Methods
Identification of studies. Epidemiologic data exists describing effects of mutation of numerous components within the DNA damage response network [16] . In order to reduce bias, explicit procedures [17] were used to systematically identify, appraise, summarize and statistically aggregate relevant studies.
Information sources. PubMed and Google Scholar databases were systematically searched Simplified model for a double strand break repair subroutine emphasizing components that have epidemiologic studies measuring risks for multiple cancers beyond breast and ovarian cancer. Inactivation of ATM, Fanconi genes, or BRCA1/2 genes in hereditary conditions causes large chromosomal rearrangements, losses or gains of sections of chromosomes [11] [12] [13] [14] . BRCA2 is the same as Fanconi component D1. FA protein J is the same as BRIP1 (BRCA1 interacting protein 1). Mutation of genes encoding any of numerous pathway components produces cancers in an overlapping distribution of organs. For example, mutations in NBS1, RAD50, ATM, BRCA1, BRCA2, CHEK2, FANCJ (BRIP1), or FANCN (PALB2) have each been associated with increased breast cancer risks. Not shown are numerous interactions with other proteins and relationships to cell cycle checkpoints (see footnote). The results reported here do not require that the pathway be linear and do not preclude participation by hormones.
Footnote Details of this outlined pathway are still emerging but many publications place FA proteins in the DNA damage network including BRCA1 and BRCA2 with activation by ATM and Rad3 related (ATR) kinase [e. g. 74, 75, 11] . Of the 13 FA proteins identified, eight of these, including FANC-A, -B, -C, -E, -F, -G, -L, and -M, form a multi-subunit nuclear FA core complex. In response to replication stress, the FA core complex promotes the monoubiquitylation of the FANCD2-FANCI heterodimer, which triggers their relocalization to sites of replication stress. Cells that are deficient in any one of the eight core complex proteins are defective in monoubiquitylation of FANCD2 and FANCI. The FA core complex acts as the E3 ligase for FANCD2 and FANCI. Any mutations that disrupt ubiquitylation of FANCD2 cause FA chromosome breakages and FA hypersensitivity to DNA cross-linking agents. The other FA factors, FANCD1/BRCA2, FANCJ/BRIP, and FANCN/PALB2, are believed to function downstream of the FA core complex, possibly in the regulation of homologous recombination, also playing essential roles in lesion repair and replication fork recovery [74] . BRCA1 is essential for the formation of nuclear foci, believed to be sites of DNA repair. 
DNA Double Strand Break
up to 2010, for original epidemiologic studies of non-breast, non-ovarian cancers vs. any defect in the model pathway in Fig. 1 . 1250 articles published in the past 50 years were retrieved and copied to a database to facilitate computer searching and review. Many bibliographies were also reviewed for additional relevant references that may have been missed. No language restrictions were imposed.
Models for inflammation related cancers. From these initial surveys, results were summarized for five cancers that have widely accepted and well-known links to chronic infection as follows. Group 1: liver cancer associated with viral hepatitis such as hepatitis B or C; Groups 2-4:
vulvar, cervical, and head and neck cancers, all associated with human papilloma viruses (HPVs); and Group 5: stomach (gastric) cancer associated with helicobacter pylori.
Included research articles analyzed. Comparatively few publications describe cancer histories at sites other than breast or ovary from typed or probable mutation carriers. No studies are available that directly determine the mutation status of every member of a large cohort of nonbreast/non-ovarian cancer cases. Therefore, cohorts likely to have a mutation were included based on one or more risk factors for inheriting a mutation in the pathway containing BRCA1/2 proteins:
These cohorts had a documented mutation in the family and/or numerous breast or other cancers at age <60. Inherited defects were in FA proteins, BRCA1, BRCA2 or the upstream activator ATM.
These cohorts were: patients diagnosed with FA in specialized clinics; all cases of FA from the literature; families having members with positive BRCA1 or BRCA2 test results based in large part on breast cancers in women younger than age 60; women from cancer registries with positive test results or high probabilities of being a BRCA1 or BRCA2 mutation carrier because of strong personal or family histories of breast and ovarian cancers at young ages; male breast cancer patients younger than age 60; cancers at age <60 in blood relatives of A-T patients.
Studies containing large numbers of cancers first diagnosed at age 60 or younger lessen the influence of sporadic cancers on effect measures. Coincidentally, risk factors in normal populations for viral infections associated with specific cancers are also higher at younger ages.
Meta-analyses exclusion criteria. Studies of groups having a known probability of carrying a mutation <=20% (3 studies) were excluded. Other exclusion criteria were > 20% of subjects lost due to mortality, illness, refusal to participate, missing information, lost branches of family trees, dropouts, etc. or some other preselection such as ignoring family branches likely to have cancer.
Any of these criteria would potentially weight results for cancer survivors or people who never get cancer (7 studies) [18] .
For serial studies representing the same population, only the largest study was used (3 studies excluded). Unpublished reports, single case reports and bone marrow transplant recipients were excluded. At least three studies were required for meta-analysis.
Validity and Quality Assessment. A high quality study was considered to have the fol-lowing characteristics. The study had to (1) have sufficient follow-up (1-10 years) (2) include incidence data from >100 individuals for cancers beyond breast and ovarian cancer, (3) have a probability of mutation >20%, assuming a positive family history (4) provide relative risks for cancers beyond breast and ovarian, with confidence intervals (CIs) or sufficient data to allow calculation of RRs and CIs. If exact mutation status was not known, the probability of carrying a BRCA1 or BRCA2 mutation was estimated from other studies of similar populations or with the BRAC analysis risk calculator from Myriad Genetics.
Data extraction. The same standard protocol was followed to extract data from each included study. Data were extracted blindly several times.
Statistical analysis.
Included studies differed in the samples chosen as the mutation group and in the details of methods employed. For meta-analyses, the random effects model was used since it allows for measured effects to vary across studies and estimates the inter-study effect variance with a simple non-iterative method [19] . Studies in meta-analyses were weighted according to this model [19] . Random and fixed effects calculations almost always gave identical or very similar results.
All reported p values were derived from two-sided statistical tests.
No assumptions were made about the risk for a cancer at any individual site unless the study reported this incidence. The reasons for this were as follows. Studies with the largest populations generally reported cancers at the most anatomic sites. Most studies of heterozygotes reported an elevated overall cancer risk especially at early ages, often with some unidentified sites. However every study showed increased risks for multiple identified cancers, with some cancers again occurring at relatively early ages.
Multi-variate and subgroup analyses. The effects of different variables on the statistical results and the robustness of the results were measured by performing meta-analyses using many different combinations of studies and study arms.
Heterogeneity testing evaluated whether the effect size in different subgroups (defined biologically or medically) varied significantly from the main effect. The inconsistency of results across studies is summarized in the I² statistic, the percentage of variation across studies due to heterogeneity rather than chance. An I 2 value >50% generally indicates significant heterogeneity [20] . Heterogeneity was also calculated as non-combinability, and by a moment based method. Heterogeneity estimates can have large uncertainty, especially for few trials and were interpreted cautiously.
In some cases it was necessary to use cumulative control cancer incidences calculated using the NCI "DevCan" and "SEER" programs. 
Results
Initial search results for 5 cancer associated infection groups. From the database of 1250 articles, a shortlist was identified, consisting of 24 cohort studies containing relative risk data for cancers other than breast and ovarian in mutation carriers. From the shortlist, 11 articles (some including several study arms) met inclusion criteria, passed exclusion tests and met the criteria of quality assessment (Fig. 2) . The 11 studies were used in meta-analyses to determine whether BRCA pathway mutations led to elevated risks for five cancers, each with a known links to a chronic inflammatory infection. Table 1 summarizes details of included studies [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] , giving the characteristics of study participants and listing follow-up periods, cancers found, associated infections, effect measures, and control values.
Chronic inflammatory infections increase risks for cancers in some organs in mu-
tation carriers. Publications from basic science relevant to hypothesis; n=11
Data summarized as corroborating data Table 3 Shortlist: Publications providing relative risk data or allowing calculations of relative risks relevant to hypothesis that in ammatory infections select liver, vulva, cervix, stomach, or head and neck as target sites for cancer in mutation carriers; n=24
Publications used in meta-analyses extracted data shown in Table 1 ; n=11
Publications excluded because probability of mutation in the population known to be <20%; n=3
Publications excluded because other publications with more data superceded them; n=3
Publications excluded because of dropouts or mortality of people likely to have cancers other than breast/ovarian or because of other pre-selection; n=7 cers with well-known associations with chronic infection/inflammation -cancer of the liver, cervix, vulva, head and neck area, and stomach. Figure 3 presents this data as graphical forest plots. Table   2 summarizes meta-analyses results and includes age of onset data. Summaries in Table 2 Risks increase hundreds of times for homozygotes and up to several times for heterozygotes.
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Thus an infection known to cause chronic inflammation in a specific organ is more likely to lead to cancer in that organ if an inherited mutation is present. Onset of cancers associated with inflammation generally occurs earlier than in control populations ( Table 2 , column 3). There is enough data available to make results robust so that changing individual study inclusions or exclusions causes only small differences in the combined meta-analysis RR values.
The conclusions here were not due to differences in study methodologies or to which gene mutated. Data in Tables 1 and 2 and graphs in Fig. 3 Limitations. Limitations of these results include comparatively small sample sizes because of the rarity of hereditary diseases. Homozygous FA is especially rare so data originates from three studies involving about 2200 patients. These studies were conducted before some FA proteins were known. It was therefore necessary to consider FA proteins as a group. This is justified biologically based on their interactions (See footnote to Figure 1 ).
The combined RR values for heterozygotes (Table 2) do not represent pure populations of heterozygotes. No study tested every member of a cohort for a mutation. Cohorts in some studies
were not typed but were eligible for mutation testing based on personal or strong family histories. port for the above results was obtained by verifying that lymphocyte infiltration is present in all five organ specific cancers as a sign of chronic inflammation. Search results (Fig. 2) also included independent data supporting results summarized in Table 2 . Table 3 lists this independent evidence from 11 publications in addition to those used for statistical summaries.
Meta-analyses results agree with independent evidence. The first independent sup-
The first paragraph in Table 3 indicates that the pathway containing BRCA1/2 is the preferred method to repair DNA lesions generated by inflammatory products. BRCA-FA dependent homologous recombination is initiated by fork breakage at adducts produced by peroxynitrite derived from macrophages [33] . Peroxynitrite oxidizes guanine in DNA producing an O-acyl-isourea structure that then reacts with proteins such as histones or glycosylases to form DNA protein adducts. The lesions are so bulky that BRCA-FA dependent homologous recombination occurs in preference to nucleotide excision repair [33] . Impaired homologous recombination would thus favor dangerous gene rearrangements if less specific repair methods then operate [11] . There are also many opportunities for interstrand cross-links. Inflammatory products from immune defenses may favor cancer if essential DNA damage response defenses have been weakened because of an inherited mutation [34] . Table 3 gives further examples of completely independent evidence [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] showing that a BRCA pathway mutation magnifies cancer risks from chronic inflammation, which then becomes a major factor in determining the organ targeted by cancer.
Ovarian cancers need not originate in the ovary. Table 4 summarizes evidence from 26 studies that inflammation targets ovary and breast in mutation carriers. Regardless of mutation status, most ovarian cancer begins in the fimbriae -fingerlike projections terminating the Fallopian tubes where the ovum released from the ovary is collected. Fimbrial cancers are difficult to distinguish from ovarian cancer because of large areas of intimate contact between fimbria and ovary. The fallopian tube cancer designation requires a dominant mass and evidence of an early cancer there. However ovarian tumor bulk may be greater. In the past, ovarian and tubal cancers were grouped and coded together [25] . Tubal ligation protects against ovarian cancer in both mutation carriers and non-mutation carriers (Table 4) . Tubal ligation commonly removes sections of tubes between the uterus and fimbria, presumably preventing infection/inflammation from reaching the fimbriae/ovaries. Ovulation itself may also contribute to inflammation by causing oxidative injury to both the ovary and the fimbria. Inhibiting ovulation by oral contraceptives decreases cancer risk (Table 4) . At the site of ovum release, leukocyte invasion, release of nitric oxide and inflammatory cytokines, vasodilation, DNA repair, and tissue remodeling (resembling wound healing) all occur [55] . Table 4 also shows other associations between infection / inflammation and fimbrial-ovarian cancer. These include evidence of inflammation in fallopian tubes and in ovaries removed during prophylactic surgeries and ovarian cancer associated with use of perineal talc. Anti-inflammatory
NSAIDs reduce ovarian cancer risk in nulliparous women [56] . Hepatitis C viral proteins down regulate FA protein J, (Bach1) a helicase that interacts with BRCA1 ( Fig. 1) [38] . The hepatitis C viral protein NS3/4A interacts with ATM altering its properties [39] . Inactivation of BRCA2 is common in hepatocellular carcinoma, a cancer commonly associated with hepatitis viruses [40] .
Fancc-deficient mice exhibit enhanced inflammatory response and are hypersensitive to LPSinduced septic shock as a result of hemopoietic suppression. This exacerbated inflammatory phenotype is intrinsic to the hemopoietic system and can be corrected by the re-expression of a wild-type FANCC gene, suggesting a potential role of the FANCC protein in innate im-
Some pathway defect is frequently found in cervical cancers (mainly caused by HPVs). A mutated BRCA1 gene was detected in 13/17 precancerous lesions of the cervix [42] . 42% (34 of 81) of cervical cancers had an allelic imbalance at a locus in 11q23.1 (near or including the ATM gene) [43] .
In the Polish population, a family history of ovarian cancer and stomach cancer is associated with germ-line BRCA2 mutations [44] . The frequency of the BRCA2 6174del mutation amoung consecutive Jewish patients with stomach cancer is about 5 times higher than in the general population.
The presence of intra-epithelial CD8+ T-cells significantly correlates with loss of BRCA1 [58, 55] . This association links inflammation to mechanisms of genomic instability [58] . Infiltration of ovarian cancers by T-cells may be inflammation marking ovaries for cancer as it does in other organs, even predisposing to loss of BRCA1 [58] . An alternate explanation is that the infiltrate represents an immune response that favors further genomic instability in the tumor.
Prophylactic removal of ovaries increases risks for primary peritoneal cancer (Table 4) , which occurs in up to 5% of patients. One explanation is that wound healing increases risks for cancer in surrounding tissues. Inflammation is an essential process that occurs early in wound healing.
Breast cancer. T-cell lobulitis is frequently found in morphologically normal breast lobules removed during prophylactic mastectomies [60] [61] . The failure to find any premalignant or malignant lesion suggests that there is an immune response before the onset of hereditary breast cancer.
T-lymphocyte infiltrates predominate in hereditary breast carcinomas [60] [61] [62] , unlike diabetic lobulitis where B-cells predominate. In other systems, T-cells produce growth regulatory molecules epidermal growth factor (EGF) and fibroblast growth factor (FGF) which are both implicated in breast cancers. BRCA1 associated breast cancers have more and denser lymphocytic infiltration than sporadic cancers in a matched control group (Table 4) . Some extracted infiltrating lymphocyte populations may have tumor killing activity in vitro, suggesting the tumor overcomes such protective functions. A T-lymphocytic infiltrate is also closely associated with medullary breast carcinoma (Table 4) , a rare cancer that is more frequent in BRCA1/2 mutation carriers. The medullary cancer infiltrate contains CD4+ and CD8+ T-cells but few tumor killing NK cells [65] .
There is a strong signature for an interferon induced pathway in some breast cancer, ovarian cancer and childhood leukemia. This "infection associated gene signature" suggests a deregulated immune or inflammatory response to some pathogen (Table 4 ). In BRCA1/2 carriers, lymphoid cells are themselves at high risk for becoming malignant [11] . Hematopoietic malignancies would make immune responses in mutation carriers less effective in clearing infection and removing abnormal cells [60, 63] .
One candidate source for infection / inflammation in breast cancer are human endogenous retroviruses (HERV). HERV-like sequences are integrated within the human genome. Expression of these sequences can cause inflammatory responses. Strong antibody and T-cell responses to HERV antigens have been found in women with early onset breast cancer and other breast cancer patients (Table 4) .
Five meta-analyses including up to 91 studies, involving millions of subjects find that NSAIDs protect against breast cancer (Table 4) .
Breast tissue of women with a background of familial breast cancer have breast fibrosis and less breast differentiation than control or normal tissues [63] . This could result from infection/in- flammation mediated cell and DNA damage or deficiencies in genes required for differentiation.
Discussion
Hepatitis or human papilloma viruses or h. pylori select specific organs for cancer because their organ targets have specific receptors on the surface of cells. Then transcription factors or other host conditions that permit the infection also influence whether chronic inflammation and then cancer occurs.
Not only do genetically related cancers typically occur at young ages but specific cancers associated with viral infections have peak occurrences in younger victims. Viral hepatitis and HPV infections have peak incidences in younger people where risk factors are typically greater and risky behavior is more frequent. The peak age for cervical cancer in women is age 47. Head and neck cancer associated with HPV infection in normal males occurs as cancer of the of the oropharynx and tonsils with peak ages 55-59 [NCI SEER data]. In contrast, many sporadic cancers that are not associated with known infections typically occur at older ages.
Inherited defects in a DNA repair subroutine containing BRCA1/2 gene products amplify risks for cancers due to chronic infection or inflammation. This is a mechanism of targeting spe- The cancer targets here include hormone responsive organs in the female reproductive system and the liver where they are metabolized. In a prostate cancer model, hormone receptor complexes move regions of chromosomes into close proximity and increase risks for site specific cancer related gene fusions after DNA double strand breaks are induced by DNA radiation damage [73] . The pathway containing BRCA1/2 is probably essential to prevent some cancer related gene rearrangements [11] . A repair-deficient genetic background magnifies cancer risks from chronic infection and inflammation, which can then become especially important reasons that a particular organ develops cancer.
Conclusion
Mutations in a DNA repair subroutine dependent on BRCA1/2 genes magnify cancer risks from chronic infection and inflammation, making them especially important in selecting the site where hereditary cancer develops. Controlling chronic infections and inflammation may be a helpful option to prevent or delay cancers in mutation carriers.
